%0 Journal Article
%A Heinz, Amadeus T
%A Ebinger, Martin
%A Schönstein, Anton
%A Fuchs, Jörg
%A Timmermann, Beate
%A Seitz, Guido
%A Vokuhl, Christian
%A Münter, Marc W
%A Pajtler, Kristian
%A Stegmaier, Sabine
%A von Kalle, Thekla
%A Kratz, Christian P
%A Rößler, Jochen
%A Ljungman, Gustaf
%A Klingebiel, Thomas
%A Koscielniak, Ewa
%A Sparber-Sauer, Monika
%T Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR).
%J Pediatric blood & cancer
%V 70
%N 7
%@ 1545-5009
%C New York, NY
%I Wiley
%M DKFZ-2023-00771
%P e30363
%D 2023
%Z 2023 Jul;70(7):e30363
%X Outcome of relapsed disease of localized rhabdomyosarcoma remains poor. An individual treatment approach considering the initial systemic treatment and risk group was included in the Cooperative Weichteilsarkom Studiengruppe (CWS) Guidance.Second-line chemotherapy (sCHT) ACCTTIVE based on anthracyclines (adriamycin, carboplatin, cyclophosphamide, topotecan, vincristine, etoposide) was recommended for patients with initial low- (LR), standard- (SR), and high-risk (HR) group after initial treatment without anthracyclines. TECC (topotecan, etoposide, carboplatin, cyclophosphamide) was recommended after initial anthracycline-based regimen in the very high-risk (VHR) group. Data of patients with relapse (n = 68) registered in the European Soft Tissue Sarcoma Registry SoTiSaR (2009-2018) were retrospectively analyzed.Patients of initial LR (n = 2), SR (n = 16), HR (n = 41), and VHR (n = 9) group relapsed. sCHT consisted of ACCTTIVE (n = 36), TECC (n = 12), or other (n = 15). Resection was performed in 40/68 (59
%K Soft Tissue Sarcoma Registry (SoTiSaR) (Other)
%K localized disease (Other)
%K relapsed disease (Other)
%K rhabdomyosarcoma (Other)
%K second-line chemotherapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37066598
%R 10.1002/pbc.30363
%U https://inrepo02.dkfz.de/record/275451